Prevision Medicine AG

Based in Switzerland, Prevision Medicine AG, operates as a provider of personalized cancer drug testing services that analyze a patient’s live cancer cells against multiple treatment options to help inform treatment decisions. Based in Schlieren, Switzerland and founded in 2024, Prevision Medicine AG specializes in precision medicine solutions. The funding will be used to accelerate the commercialization of its functional precision medicine test for hematological malignancies and solid tumors. Prevision Medicine specializes in precision medicine solutions, primarily focused on oncological treatment optimization through their patented PrevisionOne platform.

The process begins with the collection of fresh biopsy samples from patients diagnosed with blood cancers or solid tumors, which are then shipped for immediate testing in their laboratory. Utilizing proprietary drug plates, the platform evaluates patient-derived living cells against a panel of over 100 standard, experimental, and off-label treatments, assessing their real-time responses. The ultimate objective is to deliver personalized clinical reports within three days, guiding oncologists in making informed decisions regarding the most effective treatment options for individual patients. Prevision Medicine caters to a diverse client base, including oncologists and healthcare institutions across Europe, particularly in Switzerland, Germany, and other European nations, and serves patients who have limited treatment options due to the efficacy of conventional therapies.

Prevision Medicine operates on a direct-to-consumer and business-to-business model, generating revenue through service fees for their ex vivo testing and clinical report generation. The company’s transactions typically occur as healthcare providers and oncologists engage their services for patients in need of personalized treatment plans. Clients can expect to pay for each individual test conducted, which is facilitated through partnerships with hospitals and outpatient clinics looking for treatment solutions. The company’s flagship service, the PrevisionOne clinical report, is central to their revenue model, offering actionable insights to enhance treatment efficacy for various cancer types.

The company plans to accelerate the commercialization of its functional precision medicine test for hematological malignancies and solid tumors, utilizing the recent funding to enhance its service offerings.